N calculation for trial about PK superiority [Power / Sample Size]

posted by dshah  – India, 2022-09-02 13:52 (1034 d 14:26 ago) – Posting: # 23262
Views: 4,958

Hi Alex!

I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,682 registered users;
48 visitors (0 registered, 48 guests [including 15 identified bots]).
Forum time: 04:18 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5